27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The FDA has signed off Chemomab Therapeutics Ltd's (NASDAQ:CMMB) Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis (SSc).
- CM-101 is a first-in-class monoclonal antibody designed to interfere with key biological pathways associated with SSc and other fibro-inflammatory diseases.
- In preclinical studies, CM-101 reduced inflammatory and fibrotic injury to the lung, skin, and vasculature—organ systems often affected in SSc patients.
- In early clinical trials, CM-101 was well-tolerated, reducing fibrogenesis-related biomarkers and demonstrating anti-inflammatory effects in patients with severe lung inflammation, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
- The FDA has granted CM-101 Orphan Drug designation for SSc and for primary sclerosing cholangitis (PSC), a rare liver disease.
- The CM-101 Phase 2 SPRING trial in PSC patients is currently ongoing.
- Price Action: CMMB shares are up 17.95% at $2.31 on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!